等待开盘 07-01 09:30:00 美东时间
+0.012
+0.04%
Arrowhead Pharmaceuticals to host cardiometabolic R&D webinar in 2026 Summer Series Arrowhead Pharmaceuticals will host Part I of its 2026 Summer Series R&D webinar on June 29, 2026 at 11:30 a.m. EDT. Session will focus on the company’s cardiometabolic RNAi pipeline, including programs targeting APO
06-18 19:30
Arrowhead Pharmaceuticals posts plozasiran renal, hepatic impairment study presentation Arrowhead published new clinical data on plozasiran, an siRNA targeting hepatic APOC3, in subjects with renal or hepatic impairment. Single 25 mg subcutaneous dose showed higher exposure: Cmax geometric mean rati
05-26 22:18
Spire's multi-source ground and space-based data fusion to power real-time aircraft visibility within Amadeus' Virtual Airport Operations Center (vAPOC)Spire Global, Inc. (NYSE:SPIR) ("Spire" or "the Company"), a global
05-19 18:48
Spire Global supplies real-time aircraft tracking data for Amadeus virtual airport operations platform Spire Global entered an agreement with Amadeus to integrate its fused ground-based and space-based ADS-B aircraft tracking data into Amadeus’ Virtual Airport Operations Center (vAPOC). The integrat
05-19 18:45
ROI-US jobs data forces gaze back from Mideast mayhem to AI 'doom': McGeever The opinions expressed here are those of the author , a columnist for Reuters By Jamie McGeever ORLANDO, Florida, March 5 (Reuters) - With war still raging in the Middle East , investors on Friday will, at least temporarily
03-05 22:00
①小核酸药物技术为何近期频繁获得国际制药巨头的高额授权合作? ②在2026年开年创新药BD交易规模已达332.8亿美元的背景下,合作热潮是否可持续?
02-12 10:13
Arrowhead Pharmaceuticals Launches Phase 1/2a Trial of Dual-Target RNAi Therapy for Mixed Hyperlipidemia Arrowhead Pharmaceuticals Inc. has announced the initiation of a Phase 1/2a clinical trial for ARO-DIMER-PA, an investigational RNA interference (RNAi) therapeutic being developed for the treatme
01-28 01:02
Arrowhead Pharmaceuticals Inc. has released a corporate presentation highlighting its recent achievements and future plans. The company reported its first commercial launch in 2025 with REDEMPLO® (plo...
2025-12-08 10:05